In one paragraphArticle in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Vladimir A GushchinFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0002-9397-3762 Andrei E SiniavinFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0001-7576-2059 Andrei A PochtovyiFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0003-1107-9351 Alina S DzharullaevaFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0003-1743-0798 Dmitriy N ShcherbininFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0002-8518-1669 Anastasia S UngurFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0003-3187-8572 Amir I TukhvatulinFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0001-8506-2339 Inna V ShuliakovaFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Denis A KleymenovFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0001-9422-7238 Elena P MazuninaFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0003-0701-5152 Evgeniia N BykoniaFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0002-2269-1469 Sofia R KozlovaFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0009-0009-6196-8262 Evgeny V UsachevFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0001-5197-2465 Ilya D ZorkovFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Daria M GrousovaFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Anna A IliukhinaFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0003-0728-5478 Alexander L GintsburgFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Denis Y LogunovFederal State Budget Institution "National Research Center for Epidemiology and Microbiology Named After the Honorary Academician N.F. Gamaleya", The Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Funding
This research was funded by the Ministry of Health of the Russian Federation, the Government assignment "Adaptation of neoantigen-specific therapeutic mRNA vaccine principles for person-alized systemic immunotherapy of malignant neoplasms for human use" 125021101877-7
6 · The paper itselfAbstract
BACKGROUND/
objectivesEpitope-based mRNA vaccines represent a promising strategy for eliciting protective T-cell immunity against SARS-CoV-2 and as well as for non-infectious mRNA-based vaccines. However, how the structural architecture of vaccine constructs (including epitope arrangement, linker composition, signal peptide presence, and the combination of MHC class I and II epitopes) shapes the quality of T-cell responses remains poorly understood.
methodsTen tandem minigene mRNA constructs (Cons1-10) encoding different combinations of MHC class I and class II epitopes from SARS-CoV-2 proteins (S, N, M, ORF3a) were designed, encapsulated in lipid nanoparticles, and administered to C57BL/6 mice. Immunogenicity was assessed by cytokine profiling (IFN-γ, IL-2, IL-4, IL-10) and T-cell proliferation assays. Protective efficacy was evaluated in K18-hACE2 transgenic mice challenged with SARS-CoV-2.
resultsConstructs lacking a signal peptide and enriched in MHC class I-restricted epitopes induced robust Th1 responses and strong CD8
conclusionsThese findings establish a direct link between construct design parameters and T-cell polarization quality, and provide a rational framework for next-generation epitope-based mRNA vaccine development.
Indexed as
CD8 T cellsepitope-based vaccineMHC I/IImRNA vaccineSARS-CoV-2T-cell response
Identifiers
PMID41893817
PMCPMC13030834
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390